Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,233 total articles
Daqo New Energy (DQ) looks like a classic cyclical turnaround: utilization recovering, management buying shares back and a deeply discounted market cap. This trade idea lays out a mid-term long with an entry at $23.50, a $31.00 target and a $19.00 stop, backed by operational and policy catalysts while clearly flagging the industry-level risks that …
SCZ (iShares MSCI EAFE Small-Cap ETF) offers targeted exposure to non-U.S. small caps trading below their short-term moving averages, with a 2.6% yield, a market cap of roughly $13.4B and valuation metrics that read as reasonable. Technicals are oversold (RSI ~30) and price sits near $79. A measured long trade for the next 45 trading days balances …
Shift4 (FOUR) has been cut roughly in half from its highs, trading near its 52-week low while reporting strong revenue growth and solid free cash flow. Technical oversold conditions, concentrated short interest and recent institutional buying create an asymmetric risk/reward for a recovery trade. This note lays out an actionable mid-term trade plan…
Shift4 has tumbled from its 52-week high while keeping solid revenue and cash generation. At current levels the stock offers a recovery asymmetric versus larger incumbents, but operational and leadership questions remain. This piece lays out a concrete long trade, catalysts to watch, and the risks that would flip the thesis.
Copart's shares have been hammered after a string of weaker prints and a visible derating from 52-week highs. Fundamentals remain intact - cash flow is strong, ROE is healthy and the market cap is now roughly $32.7B - creating a favorable entry after technical oversold readings. We upgrade to Buy and lay out entry, stop, and target for a mid-term/s…
enGene (ENGN) is a clinical-stage developer of DDX non-viral gene-delivery technology. With a market cap around $487M, low reported float (~48M shares), a history of financing at $10/share, and upcoming 2026 operational catalysts likely tied to trials and regulatory activity, the stock offers an asymmetric risk-reward for a disciplined long trade. …
GE Vernova (GEV) is a high-quality energy-industrial play with a deep backlog, improving free cash flow and strong ROE. Valuation looks rich on headline multiples, but the combination of a $150B-plus backlog, $3.71B in free cash flow and structural demand from data center electrification supports upside to $1,000 over the next 180 trading days. Ent…
Nvidia’s position in AI infrastructure continues to deepen: dominant share of AI accelerators, massive ecosystem commitments to suppliers and partners, and strong free cash flow give the company optionality to control the stack. Technicals and short-term macro risks argue for careful sizing, but over a 180-trading-day horizon the case for a long re…
Nvidia's strategic tie-up with Palantir creates a credible pathway for government-grade, data-sovereign AI deployments. That should accelerate sales of Blackwell hardware, DGX/Cloud services and higher-margin software bundles, making the partnership a potential multi-quarter revenue and margin catalyst. Trade plan: enter $183.60, target $250.00, st…
Interim data and a favorable regulatory backdrop have increased the probability Solid Biosciences can start its next clinical trial in Q1 2026. The shares are trading below $8 with a market cap near $600M, leaving room for a re-rate if the company executes. This trade idea lays out a long entry, stop, targets and the risks to watch across a 46-180 …
Fastenal's distribution franchise runs like clockwork: high returns, low leverage, and predictable free cash flow. At $45.69 the stock looks like a defensive industrial compounder — expensive on multiples but structurally advantaged. This trade idea lays out an actionable long with entry, stop and targets across a 45- to 180-trading-day horizon and…
Datadog has taken a hit from the AI-driven software rotation, but its platform remains central to enterprise operations. With a $45B market cap, $1.0B in free cash flow and a series of AI-focused partnerships, the stock looks like an actionable upgrade trade. We lay out entry, stop, target and the catalysts that could re-rate the multiple.
D-Wave has begun to prove its go-to-market story: triple-digit revenue growth, a string of meaningful bookings and a large customer win. The balance sheet and recent acquisition give the company optionality while the stock's retreat compresses downside for patient, risk-aware traders. This trade idea lays out a long entry, stop, targets and the cat…
Cisco trades at roughly $307.7B market cap, ~27x earnings and an EV/EBITDA of 21.3 despite low-single-digit free cash flow yield and a mature networking business. Technicals show weakening momentum and short activity is elevated. This is a tactical short idea with a clear entry at $78.00, stop at $83.50 and a mid-term target of $70.00 (45 trading d…
Netskope plunged to the low $9s on heavy volume after post-IPO selling. Fundamentals show durable growth and product momentum, but GAAP losses and mixed guidance keep sentiment fragile. This trade targets a mid-term rebound off oversold technicals and crowded short positioning.
monday.com plunged from its 2025 highs and now trades at a valuation that assumes meaningful deceleration. I view the sell-off as a tactical buying opportunity for disciplined, mid-term traders who accept company-specific and AI-related execution risk. Entry $75.00, target $128.00, stop $66.00; horizon: mid term (45 trading days).
Dollar General pulled back sharply after conservative fiscal-2026 guidance, but the underlying economics remain attractive: solid free cash flow ($2.34B), steady EPS ($5.80 trailing), and a resilient business model as consumers trade down. This trade idea is a mid-term swing buy on weakness with a clear entry, stop and target.
Iridium (IRDM) has jumped from last year's lows and is trading well above several moving averages. Fundamentals remain solid — free cash flow near $300M and a healthy ROE — but leverage, a high price/book, and an RSI flirting with overbought levels argue the rally is vulnerable. We lay out an actionable short with a clear entry, stop and target for…
Edgewell Personal Care (EPC) trades at an undemanding valuation (market cap ~$895M, EV/EBITDA ~9.5) after divesting its feminine care business. With steady free cash flow, a 3% dividend, and clear cost-money levers, the stock offers a risk-reward profile worth a tactical long. Entry $19.15, target $26.00, stop $17.00; horizon: long term (180 tradin…
We upgrade Rocket Lab (RKLB) to Buy after the company’s strategic reset and a string of operational wins. Q4 strength, a $1.85 billion backlog, $2.48 billion in cash, and growing defense revenue (including repeat hypersonic missions) create a reasonable risk/reward for a long trade. The stock remains richly valued, so position sizing and a discipli…
Amgen's recent rally looks fundamentally supported by optimism around MariTide's once‑monthly obesity program and better‑than‑feared osteoporosis performance. The company trades at ~$370 with a market cap near $199.5B, generates roughly $8.1B in free cash flow and carries a P/E ~26.5. This trade idea is a mid‑term long: enter at $370.08, target $39…
Rheinmetall is a direct play on a defense upgrade cycle that is expanding beyond ammunition and armored vehicles into high-margin sensors and electronics. With hyperspectral imaging markets forecast to double from $0.92B in 2025 to $1.83B by 2030 (CAGR 14.7%), Rheinmetall's push into sensors, electro-optics, and integrated platform upgrades gives i…
Lumentum's optics business is moving from quiet growth to visible AI-infrastructure demand. Recent news - including an Nvidia-backed investment and upcoming S&P 500 inclusion - should tighten supply/demand in the near term. The stock is richly valued on history, but the trade offers a defined risk-reward if you buy the narrative and the catalysts p…
Novo Nordisk is priced like a company that has lost its core franchise. The market reaction has created a high-conviction, asymmetric trade: buy Novo at current levels to capture upside from renewed distribution (Hims & Hers), product life-cycle catalysts and a recovery in investor sentiment. Entry at $38.40, stop $35.00, target $60.00, horizon: lo…
Broadcom is morphing from a diversified semiconductor and software supplier into a high-cash-flow AI infrastructure powerhouse. With custom AI ASICs and next-gen optical DSPs ramping, free cash flow of roughly $26.9B and a fortress balance sheet, the stock merits a long trade with a $400 target and a $295 stop. Valuation is rich, but execution and …
